Testing FZ-AD005 for high-grade glioma
Part of Cancer clinical trials.
This trial tests a new drug called FZ-AD005 for people with high-grade glioma (a type of brain tumor). The drug targets a protein called DLL3 found on some tumor cells. It is for patients who either just finished radiation for a specific glioma type or have a glioma that came back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma (a fast-growing brain tumor) that is either a specific type called diffuse midline glioma with an H3 K27 mutation just after radiation, or a glioma that has come back or gotten worse after standard treatment.
- You must have had a tumor tissue test that shows a protein called DLL3 is present on your cancer cells.
- You are between 18 and 70 years old and able to take care of most daily tasks (Karnofsky score 60 or 70).
- If you take steroids for brain swelling, your dose must be stable and low (5 mg or less of dexamethasone per day) for at least a week before starting.
- You cannot have had certain other cancers, serious heart or lung problems, active infections, or untreated brain swelling that could be dangerous.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Hear when a new High Grade Glioma (III or IV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.